Regulatory & Legal

A Quebec partnership has completed the first building with carbon-negative, insulated blocks, a breakthrough aiming to decarbonize construction from the ground up.

FreeCast is set for a Nasdaq direct listing, but SEC filings reveal massive losses and a "going concern" warning, raising questions about its future.

With a $2M JobsOhio grant, Hartzell's new Innovation Center propels Ohio's aerospace legacy into the era of advanced air mobility and high-tech jobs.

A new study reveals adults with IDD are 9x more likely to have anxiety or depression, yet face immense barriers to care. This is a systemic failure.

A startup founded by elite tech and military vets has won a $30M federal contract to unleash autonomous AI agents against next-gen cyber threats.

Dr. Joss Reimer, a veteran of Manitoba's COVID-19 response, takes the helm at PHAC, facing a slate of crises from measles to misinformation.

A push to simplify mortgage credit checks could raise rates and reduce access to loans, with a new study revealing the hidden financial risks for consumers.

A new subcontract for AI edge systems, backed by key industry investors, highlights a major shift toward real-time, autonomous intelligence on the battlefield.

Record storms and global events are disrupting travel. Your airline refund won't cover everything. Here’s how to protect your vacation investment.

A multi-government partnership injects over $55 million into Burnaby's Metrotown, creating 116 below-market rental homes for essential workers.

Trigon Property Development reported a €99,507 net loss for 2025 after generating zero revenue, highlighting the risks of its single-project strategy.

Olenox Industries adds former Under Secretary of State Paula Dobriansky to its board, a move signaling a strategic push into complex global markets.

As Canada launches a bold defence strategy, drone-maker Draganfly recruits a former top general to navigate the multi-billion dollar opportunity.

New data reveals a targeted therapy can help patients with a rare, aggressive lung cancer even after their disease shows signs of worsening.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

The REIT is offering a high 9.75% yield for new notes, but investors who refuse the swap could see their current protections vanish. A critical choice looms.

Latest drill results confirm major expansion at Tesla Zone, as Foran Mining pushes toward a multi-deposit critical minerals camp in Saskatchewan.

Sai Life Sciences' plan to hire 700+ professionals underscores a global shift, positioning India as a critical hub for pharmaceutical R&D and manufacturing.